Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ARQ 531|
ARQ 531 is an ATP-competitive BTK inhibitor with activity against wild-type BTK and BTK C481S and has been demonstrated to inhibit migration and viability of chronic lymphocytic leukemia cells (ASH, Blood 2016 128:3232).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ARQ 531||ARQ531|ARQ-531|Nemtabrutinib|MK-1026|MK 1026|MK1026||BTK inhibitor 28||ARQ 531 is an ATP-competitive BTK inhibitor with activity against wild-type BTK and BTK C481S, which may inhibit migration and viability of tumor cells (PMID: 30093506, PMID: 31992353).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||acute myeloid leukemia||not predictive||ARQ 531||Preclinical - Patient cell culture||Actionable||In a preclinical study, ARQ 531 treatment induced apoptosis in acute myeloid leukemia cells harboring either FLT3 exon 14 insertion (FLT3-ITD) or wild-type FLT3, and inhibited proliferation and reduced colony formation in patient cells derived from acute myeloid leukemia independent of FLT3 status in culture (PMID: 31992353).||31992353|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04728893||Phase II||ARQ 531||Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003)||Recruiting||USA | ITA | FRA | ESP | CAN||7|
|NCT03162536||Phase I||ARQ 531||Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies||Active, not recruiting||USA||0|